Respiratory Syncytial Virus News and Research

RSS

Changing upper respiratory microbiome in children related to SARS-CoV-2 susceptibility

Researchers tested the nasopharyngeal microbiome of children up to 21 years old and found the microbiome changes with age. Specific bacteria, whose abundance also changes with age, are associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection susceptibility and severity.

25 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

Could cinnamon modulate the immune response in severe COVID-19?

A new study describes the potential for two common plant products to make a difference in the management of severe COVID-19.

18 Mar 2021

Microbiota modulation and re-establishment of eubiosis could help curb COVID-19 complications

In the paper published in the journal Frontiers in Immunology, the researchers noted that since both the respiratory tract and the gastrointestinal mucosa are affected in COVID-19, it is possible that adjunctive therapies that modulate the gut-lung axis.

18 Mar 2021

Tiny antibodies naturally generated by llamas can be effective against COVID-19

As the fight against COVID-19 continues, scientists have turned to an unlikely source for a potentially effective treatment: tiny antibodies naturally generated by llamas.

10 Mar 2021

Obesity may reduce COVID-19 vaccine efficacy, say researchers

A startling indicates that obesity may reduce the immune response to the current COVID-19 vaccines, along with other factors like age and sex. This could have significant implications for vaccination strategies in obese people.

3 Mar 2021

SARS-CoV-2 viremia predicts severe COVID-19 disease outcomes

The SARS-CoV-2 plasma viremia has been linked to severe disease and death in COVID-19 cases in small-scale cohort studies. The current study, published on the pre-print server medRxiv, aimed to study the mechanisms behind this relationship.

2 Mar 2021

KAUST researchers develop a safe, fast and cheap testing method to detect viruses

A safe, fast and cheap testing method that uses magnetic nanoparticles to detect viruses in both clinical and wastewater samples has been developed by KAUST researchers.

25 Feb 2021

Novel single-particle digital assay using plasmonic nanobubbles

An interdisciplinary team from the University of Texas applied DIAMOND to the respiratory syncytial virus (RSV) diagnostics and demonstrated that DIAMOND is 150 times more sensitive than commercial lateral flow assays. They found that the measurements are completed within 2 minutes. The results of this study are published on the medRxiv* preprint server.

25 Feb 2021

New rapid diagnostic tests can differentiate between COVID-19 variants and multiple viruses

University of Minnesota Medical School researchers have developed two new rapid diagnostic tests for COVID-19 - one to detect COVID-19 variants and one to help differentiate with other illnesses that have COVID-19-like symptoms.

23 Feb 2021

Nanobodies protect against SARS-CoV-2 variants in animal model

Nanobodies are a potential therapeutic strategy for treating COVID-19. While many previous studies report nanobodies active against SARS-CoV-2 in vitro, none have been evaluated via animal models' intranasal administration.

15 Feb 2021

Relaxed control measures are driving wintertime outbreaks of COVID-19

Wintertime outbreaks of COVID-19 have been largely driven by whether people adhere to control measures such as mask wearing and social distancing, according to a study published Feb. 8 in Nature Communications by Princeton University researchers.

10 Feb 2021

Natural reinfection with respiratory syncytial virus varies based on antibody response

Researchers at Baylor College of Medicine found that while most individuals responded to respiratory syncytial virus (RSV) natural reinfection with a typical sustained antibody response associated with protection, a few individuals surprisingly responded atypically, not being able to sustain the antibody response, which declined to levels that made the individuals susceptible to RSV reinfection.

5 Feb 2021

Differences in immune response to SARS-CoV-2 determine disease severity, study finds

Researchers investigate host responses to SARS-CoV-2, respiratory syncytial virus (RSV), and influenza virus (IV) in the nasal mucosa in children and adults.

2 Feb 2021

Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials

A new study shows that a single immunization with a low dose of the Ad26.COV2.S vaccine – also known as the ‘Johnson & Johnson vaccine’ – effectively protected against SARS-CoV-2 challenge in rhesus macaques.

2 Feb 2021

Iron-carrying extracellular vesicles promote viral-bacterial co-infection

The mechanism by which acute viral respiratory infections promote secondary bacterial growth and infection in the airways depends on iron-carrying extracellular sacs secreted by the cells lining the host's airways, report researchers from the University of Pittsburgh School of Medicine in a paper published today in Cell Reports.

26 Jan 2021

COVID-19 has transformed the world of vaccines

Researchers at GlaxoSmithKline (GSK) in Italy and Belgium say the coronavirus disease 2019 (COVID-19) pandemic is transforming the world of vaccinology by accelerating vaccine development and the availability of powerful technologies.

20 Jan 2021

Moderna to develop three new mRNA-based vaccines against HIV, influenza, and the Nipah virus

Morderna has announced plans to develop a range of new mRNA-based vaccines against other viruses, including the influenza virus, human immunodeficiency virus (HIV), and the Nipah virus.

13 Jan 2021

SARS-CoV-2 may join the ranks of mild cold-causing coronaviruses

What is the endgame for SARS-CoV-2, the virus that is causing worldwide devastation? If it becomes endemic -- circulating in the general population -- and most people are exposed in childhood, SARS-CoV-2 may join the ranks of mild cold-causing coronaviruses that currently circulate in humans, according to a model developed by Emory and Penn State scientists.